Ion Beam Applications Logo
BE0003766806
914998
IBAB.BR

Ion Beam Applications

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Ion Beam Applications wins major German order for 'Be Efficient' sterilization solution

    Ion Beam Applications has secured an order in Germany for its 'Be Efficient' electron‑beam sterilization solution; the customer was not disclosed. The order has a list price of about €11–18 million depending on configuration and is intended to deliver high throughput, operational efficiency and lower operating costs. IBA sees long‑term growth opportunities in the business unit, particularly in the context of radiopharmaceutical and environmental applications. » More on deraktionaer.de


  • Ion Beam Applications wins US order for twelve Cyclone cyclotrons

    Ion Beam Applications is to deliver twelve Cyclone-KIUBE-PET cyclotrons to a leading US manufacturer; the order value is expected to be at least around €30 million. At the same time, IBA is expanding Actinium-225 production through the PanTera joint venture with SCK CEN, positioning itself centrally in the growing radiopharma value chain. The company is presented as an important supplier for novel theranostic cancer treatments; the stock is described as attractively valued with a P/E ratio of 15. » More on deraktionaer.de


  • Ion Beam Applications: pre-tax profit rises 920% after strong half-year

    Ion Beam Applications reports net revenues of €323.7m in the first half (+6%) and a gross margin of 33.7% (+4.2 percentage points). Adjusted EBIT climbed to €17.6m (+66%), while pre-tax profit rose to €12.3m (+920%). The company confirms its 2026 guidance (adjusted EBIT at least €32m) and shows an order backlog of around €1.6bn, about half in high-margin service offerings. In addition, the joint venture Pantera is advancing commercial-scale production of the radioisotope actinium-225 and preparing regulatory filings for clinical trials. » More on deraktionaer.de


  • Ion Beam Applications receives major order for Brazil and remains attractively valued

    Ion Beam Applications has received an order for a ProteusONE proton therapy system in Barra da Tijuca, Rio de Janeiro, primarily to treat pediatric patients. The group reports a record order backlog of around €1.6 billion and calculates the end-customer price including maintenance at €35–45 million. The stock recently entered an upward trend; the price-to-earnings ratio (P/E) for the coming year is about 15, so the valuation is still considered attractive. » More on deraktionaer.de


  • Ion Beam Applications receives fourth ProteusONE order in Taiwan

    Ion Beam Applications has won another order for a ProteusONE proton therapy system for MacKay Memorial Hospital in Taiwan. The company also secured the quality assurance package from IBA Dosimetry; delivery and installation are planned to enable treatment start in 2029. The order value is expected to be between 35 and 45 million euros and strengthens IBA's market position as well as its visibility in the order books. » More on deraktionaer.de

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Ion Beam Applications has already paid €0.25 in dividends. The last payout was in July.

Financials

In the last quarter, Ion Beam Applications had revenue of €323.7M and net profit of €9.3M
(EUR) June 2026
YoY
Revenue 323.7M -
Gross profit 108.9M -
Net profit 9.3M -
EBITDA 23.9M -

Fundamentals

Metric Value
Market capitalization
€481.69M
Number of shares
29.16M
52-week high/low
€17.76 - €9.90
Dividend yield
1.49%
Dividends TTM
€0.25
Beta
1.23
P/E ratio
19.90
PEG ratio
0.41
P/B ratio
4.20
P/S ratio
0.75

Company profile

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Name
Ion Beam Applications
CEO
Olivier Legrain
Headquarters Louvain-la-Neuve, bu
Belgium
Website
Sector
Health Care
Industry
Health Care Technology
IPO
01/04/2000
Employees 2,264

Ticker symbols

Exchange Symbol
Euronext
IBAB.BR
Pnk
IOBCF
Brussels Stock Exchange
IBAB.BR
Frankfurt
IOB.F
DĂĽsseldorf
IOB.DU
London
0GZK.L
MĂĽnchen
IOB.MU
🍪

Parqet  uses cookies. Learn more